Articles related to PHARMACOTHERAPY

The FDA approved a supplemental NDA adding randomized withdrawal trial data to the lumateperone label, supporting its role in long-term maintenance and relapse prevention in adults with schizophrenia.

Retrospective analysis of pediatric cancer survivors identified low overall CHIP prevalence, with antimetabolite therapy and methotrexate exposure emerging as the strongest treatment-associated signals.

Retrospective analyses presented at SABCS 2025 associated GLP-1 receptor agonist use with weight loss, mortality, and recurrence signals in breast cancer cohorts, with effects on endocrine therapy tolerability also observed.

The FDA approved vepdegestrant for ESR1-mutated, ER-positive, HER2-negative advanced breast cancer after endocrine therapy progression, marking the first regulatory approval of a PROTAC drug.

Boehringer Ingelheim’s SYNCHRONIZE-1 phase 3 trial reported 16.6% average body weight reduction with survodutide, a dual GLP-1/glucagon receptor agonist, over 76 weeks in adults without type 2 diabetes.

Rodent and non-human primate studies showed glucagon and GIP agonism alone produced weight loss comparable to GLP-1-containing triple agonists in a Bluewater Biosciences-funded program.